Proliferation and invasion of ovarian cancer cells are suppressed by knockdown of TRIM11

Chen,Yan; Sun,Jin; Ma,Junyan

doi:10.3892/ol.2017.6432

Proliferation and invasion of ovarian cancer cells are suppressed by knockdown of TRIM11

Authors:
- Yan Chen
- Jin Sun
- Junyan Ma
View Affiliations

Affiliations: Clinical Laboratory, The Women's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, P.R. China, Women's Reproductive Health Laboratory of Zhejiang, The Women's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, P.R. China
Published online on: June 20, 2017 https://doi.org/10.3892/ol.2017.6432
Pages: 2125-2130
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tripartite motif-containing (TRIM)11, an E3 ubiquitin ligase, is involved in the development of the nervous system. As an oncogene, it has also been identified in glioma, lung and colon cancer. However, few studies have been conducted on TRIM11 expression and functions in ovarian cancer. In the present study, we found that TRIM11 expression was obviously elevated in ovarian cancer tissues compared to adjacent non-cancerous tissues. Depletion of TRIM11 in A2780 and SK-OV-3 ovarian cancer cells by transfection of specific small interfering RNA significantly suppressed proliferation and inhibited invasion of cells, even induced apoptosis as indicated by both Cell Counting Kit-8, Annexin V/propidium iodide staining and Transwell assay. Furthermore, we explored the underlying mechanisms. Knockdown of TRIM11 not only affects the expression of cell apoptosis-related (Bcl-2 and Bax) and invasion-related proteins [matrix metalloproteinase (MMP)-2 and MMP-9], but also reduced the phosphorylation levels of ERK and AKT. In conclusion, we showed that TRIM11 was upregulated in ovarian cancer tissue samples and that TRIM11 may serve as an oncogene in ovarian cancer.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S and Beller U: Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 95 Suppl 1:161–192. 2006. View Article : Google Scholar : PubMed/NCBI
3	Hatakeyama S: TRIM proteins and cancer. Nat Rev Cancer. 11:792–804. 2011. View Article : Google Scholar : PubMed/NCBI
4	Niikura T, Hashimoto Y, Tajima H, Ishizaka M, Yamagishi Y, Kawasumi M, Nawa M, Terashita K, Aiso S and Nishimoto I: A tripartite motif protein TRIM11 binds and destabilizes Humanin, a neuroprotective peptide against Alzheimers disease-relevant insults. Eur J Neurosci. 17:1150–1158. 2003. View Article : Google Scholar : PubMed/NCBI
5	Hong SJ, Chae H, Lardaro T, Hong S and Kim KS: Trim11 increases expression of dopamine beta-hydroxylase gene by interacting with Phox2b. Biochem Biophys Res Commun. 368:650–655. 2008. View Article : Google Scholar : PubMed/NCBI
6	Tuoc TC and Stoykova A: Trim11 modulates the function of neurogenic transcription factor Pax6 through ubiquitin-proteosome system. Genes Dev. 22:1972–1986. 2008. View Article : Google Scholar : PubMed/NCBI
7	Ishikawa H, Tachikawa H, Miura Y and Takahashi N: TRIM11 binds to and destabilizes a key component of the activator-mediated cofactor complex (ARC105) through the ubiquitin-proteasome system. FEBS Lett. 580:4784–4792. 2006. View Article : Google Scholar : PubMed/NCBI
8	Di K, Linskey ME and Bota DA: TRIM11 is overexpressed in high-grade gliomas and promotes proliferation, invasion, migration and glial tumor growth. Oncogene. 32:5038–5047. 2013. View Article : Google Scholar : PubMed/NCBI
9	Wang X, Shi W, Shi H, Lu S, Wang K, Sun C, He J, Jin W, Lv X, Zou H and Shu Y: TRIM11 overexpression promotes proliferation, migration and invasion of lung cancer cells. J Exp Clin Cancer Res. 35:1002016. View Article : Google Scholar : PubMed/NCBI
10	Yin Y, Zhong J, Li S-W, Li JZ, Zhou M, Chen Y, Sang Y and Liu L: TRIM11, a direct target of miR-24-3p, promotes cell proliferation and inhibits apoptosis in colon cancer. Oncotarget. 7:86755–86765. 2016.PubMed/NCBI
11	Sakuma M, Akahira J, Suzuki T, Inoue S, Ito K, Moriya T, Sasano H, Okamura K and Yaegashi N: Expression of estrogen-responsive finger protein (Efp) is associated with advanced disease in human epithelial ovarian cancer. Gynecol Oncol. 99:664–670. 2005. View Article : Google Scholar : PubMed/NCBI
12	Ma Y, Wei Z, Bast RC Jr, Wang Z, Li Y, Gao M, Liu Y and Wang X, Guo C, Zhang L and Wang X: Downregulation of TRIM27 expression inhibits the proliferation of ovarian cancer cells in vitro and in vivo. Lab Invest. 96:37–48. 2016. View Article : Google Scholar : PubMed/NCBI
13	Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Bignotti E, Anfossi S, Gokden M, Dunn D, Roman JJ, et al: Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer. 112:14–25. 2004. View Article : Google Scholar : PubMed/NCBI
14	Tan H, Liu Z, Qi J and Chu G: Tripartite motif 16 inhibits the migration and invasion in ovarian cancer cells. Oncol Res. 25:551–558. 2017. View Article : Google Scholar : PubMed/NCBI
15	Reed JC: Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol. 7:541–546. 1995. View Article : Google Scholar : PubMed/NCBI
16	Leber MF and Efferth T: Molecular principles of cancer invasion and metastasis (Review). Int J Oncol. 34:881–895. 2009.PubMed/NCBI
17	Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G, Nesland JM, Berner A, Bryne M and Reich R: High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis. 17:799–808. 1999. View Article : Google Scholar : PubMed/NCBI
18	Downward J: PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol. 15:177–182. 2004. View Article : Google Scholar : PubMed/NCBI
19	Boucher MJ, Morisset J, Vachon PH, Reed JC, Lainé J and Rivard N: MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem. 79:355–369. 2000. View Article : Google Scholar : PubMed/NCBI
20	Jung C-H, Kim EM, Park JK, Hwang SG, Moon SK, Kim WJ and Um HD: Bmal1 suppresses cancer cell invasion by blocking the phosphoinositide 3-kinase-Akt-MMP-2 signaling pathway. Oncol Rep. 29:2109–2113. 2013.PubMed/NCBI
21	Adya R, Tan BK, Punn A, Chen J and Randeva HS: Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res. 78:356–365. 2008. View Article : Google Scholar : PubMed/NCBI
22	Morgensztern D and McLeod HL: PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs. 16:797–803. 2005. View Article : Google Scholar : PubMed/NCBI
23	Kohno M and Pouyssegur J: Targeting the ERK signaling pathway in cancer therapy. Ann Med. 38:200–211. 2006. View Article : Google Scholar : PubMed/NCBI
24	Hill MM and Hemmings BA: Inhibition of protein kinase B/Akt. implications for cancer therapy. Pharmacol Ther. 93:243–251. 2002. View Article : Google Scholar : PubMed/NCBI